`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`MYLAN INSTITUTIONAL LLC,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`______________
`
`Case IPR2020-00324
`Patent 8,114,833
`______________
`
`
`PATENT OWNER MANDATORY NOTICE INFORMATION
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), Patent Owner, Novo Nordisk A/S (“Novo
`
`IPR2020-00324
`Patent 8,114,833
`
`Nordisk”), hereby files its Mandatory Notices:
`
`A. Real Party-in-Interest (§ 42.8(b)(1))
`
`The following real parties-in-interest are identified: Novo Nordisk A/S, Novo
`
`Nordisk Inc., Novo Holdings A/S, and Novo Nordisk Foundation.
`
`B. Related Matters (§ 42.8(b)(2))
`
`Patent Owner is aware of the following district court litigations involving U.S.
`
`Patent No. 8,114,833: Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan
`
`Institutional LLC, No. 19-cv-01551-CFC (D. Del.); Novo Nordisk Inc. and Novo
`
`Nordisk A/S v. Mylan Institutional LLC, No. 19-cv-164 (N.D. W. Va.). Case No.
`
`19-cv-01551-CFC is currently pending. Case No. 19-cv-164 has been voluntarily
`
`dismissed.
`
`U.S. Patent Application No. 16/260,204, which is pending and was filed on
`
`January 29, 2019, claims the benefit of U.S. Application No. 11/435,977, which is
`
`the application that issued as U.S. Patent No. 8,114,833.
`
`C. Counsel and Service Information (§§ 42.8(b)(3) and (4))
`
`Patent Owner identifies its lead and backup counsel as shown below:
`
`
`
`
`
`
`
`1
`
`
`
`
`Lead Counsel
`Jeffrey J. Oelke
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`joelke@fenwick.com
`USPTO Reg. No. 37,409
`
`IPR2020-00324
`Patent 8,114,833
`
`Backup Counsel
`Ryan P. Johnson
`(pro hac vice to be sought)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`ryan.johnson@fenwick.com
`
`Laura T. Moran
`(pro hac vice to be sought)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`laura.moran@fenwick.com
`
`
`Please address all correspondence to the lead and backup counsel at the above
`
`addresses and to Novo833IPR@fenwick.com. Patent Owner consents to electronic
`
`service to the e-mail addresses above for lead and backup counsel and to
`
`Novo833IPR@fenwick.com.
`
`D.
`
`Patent Owner Preliminary Response
`
`Patent Owner reserves the right to file a preliminary response at a separate
`
`date.
`
`E.
`
`Patent Owner Power of Attorney
`
`A Power of Attorney to transact all business in the United States Patent and
`
`Trademark office in connection with above-referenced Inter Partes Review from
`
`Patent Owner Novo Nordisk A/S to the above-designated counsel at Fenwick &
`
`2
`
`
`
`
`West LLP is being filed concurrently with these Mandatory Notices.
`
`IPR2020-00324
`Patent 8,114,833
`
`Dated: January 9, 2020
`
`
`
`
`
`Respectfully submitted,
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`joelke@fenwick.com
`
`Counsel for Novo Nordisk A/S
`
`3
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6 and 42.105, I hereby certify that the foregoing
`
`Patent Owner Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on
`
`January 9, 2020, by filing this document through the Patent Trial and Appeal Board
`
`End to End System, as well as delivering a copy via electronic mail upon the
`
`following attorneys of record for the Petitioner:
`
`Brandon M. White
`Lara Dueppen
`Perkins Coie LLP
`white-ptab@perkinscoie.com
`dueppen-ptab@perkinscoie.com
`
`
`Date: January 9, 2020
`
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`
`Counsel for Novo Nordisk A/S
`
`
`
`